

Appl. No. 10/031,342

AMENDMENTS TO THE CLAIMS

Claims 1-80 Canceled

81. (Currently Amended) A GDF-8 analogue comprising a GDF-8 polypeptide that has been modified by means of at least ~~one modification that comprises substituting~~ two substitutions of a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is selected from more than one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12, or that has been modified by inserting at least one first amino acid sequence in SEQ ID NO: 11 or 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from at one or more of residues 1-12, 18-30, 42-51, 82-86 and 105-109 in SEQ ID NO: 11 or 12.

82. (Previously Presented) An immunogenic composition comprising an immunologically effective amount of a DGF-8 analogue according to claim 81, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

83. (Previously Presented) An immunogenic composition according to claim 82, wherein the adjuvant is selected from the group consisting of the adjuvants of claim 73.

84-102 Canceled

103. (Currently Amended) A GDF-8 analogue comprising a GDF-8 polypeptide that has been modified by means of at least ~~one modification that comprises substituting at least two~~ substitutions of a first amino acid sequence in SEQ ID NO: 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is selected from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 12 or that has been modified by inserting at least one first amino acid sequence in SEQ ID NO: 11 or 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from at one or more of residues 1-12, 18-30, 42-51, 82-86, and 105-109 in SEQ ID NO: 12.

BEST AVAILABLE COPY

Appl. No. 10/031,342

104. (Previously Presented) The GDF-8 analogue according to claim 103, wherein the modification is made in residues 18-41 of SEQ ID NO: 12.

105. (Currently Amended) A GDF-8 analogue comprising a GDF-8 polypeptide that has been modified by at least one modification selected from the group consisting of

- substituting a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12;
 - inserting at least one amino acid which comprises a foreign T_H epitope at one or more of residues 1-12, 18-30, 42-51, 82-86 or 105-109 in SEQ ID NO: 11 or 12,
 - ~~- adding an amino acid sequence which comprises a foreign T_H epitope at the N- or C-terminus to SEQ ID NO: 11 or 12;~~
 - substituting a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is a loop area or a flexible terminus in the GDF-8 polypeptide comprising SEQ ID NO: 11 or 12; and
 - inserting at least one amino acid sequence which comprises a foreign T_H epitope into a loop areas or in a flexible terminus in the GDF-8 polypeptide comprising SEQ ID NO: 11 or 12;
- wherein the number of amino acid additions, insertions, deletions, and substitutions does not exceed 60.

106. (Previously Presented) The method according to claim 105, wherein the foreign T_H epitope is introduced by means of insertion.

107. Canceled

108. (Previously Presented) The method according to claim 105, wherein the foreign T_H epitope is introduced by means of substitution.

109. (Previously Presented) The method according to claim 105, wherein the foreign T_H epitope is promiscuous.

BEST AVAILABLE COPY

Appl. No. 10/031,342

110. **(Previously Presented)** An immunogenic composition comprising an immunologically effective amount of a GDF-8 analogue according to claim 105, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

BEST AVAILABLE COPY